Great write up on PTX. Interesting that Ph2 breast cancer continues to do well - 40% complete response and 60% partial and only one more patient required to have a complete response to expand the Ph2 trial - but no real insights yet to AML. Other interesting point that
“Ptx 200 we might partner, but with PTX-1 00, we could realistically carry that ourselves because we have a fast-track development plan,” he said.
http://ptxtherapeutics.com/wp-content/uploads/2018/08/180829_PTX_MED_BioWorld-Media-Release.pdf
Ann: June 2018 Appendix 4C - Quarterly, page-47
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $31.40M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.9¢ | $72.73K | 1.802M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 436541 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 560576 | 1 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |